Revolutionizing Drug Development: The Impact of AI Tool ‘KIBIT’

The COVID-19 pandemic underscored the critical need for drug discovery, which now demands substantial financial resources. To tackle rising pharmaceutical costs, AI drug discovery is gaining traction, with Japan’s KIBIT AI tool poised to make significant advancements. In the U.S., President Trump issued executive orders to mandate reduction of high drug prices, which are notably higher than in Japan and the OECD average. Japan has a national pricing system for medicines, enabling more affordable access. However, pharmaceutical companies face ballooning R&D costs, with Japanese spending increasing significantly over the decades. The probability of successful drug development has decreased, further complicating financial viability. KIBIT, developed by FRONTEO, addresses the crucial initial stage of drug discovery—target identification—by leveraging natural language processing to analyze extensive medical literature. This innovation could transform drug discovery, ultimately aiming to provide affordable medications without the need for governmental intervention, as several pharmaceutical firms already adopt KIBIT.

Source link